Trials / No Longer Available
No Longer AvailableNCT03067935
Individual Patient Expanded Access-Glembatumumab Vedotin
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Celldex Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Celldex endeavors to make investigational products available to patients with life-threatening diseases who have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. Requests for expanded access to glembatumumab vedotin in patients with gpNMB expressing triple negative breast cancer will be considered.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | glembatumumab vedotin |
Timeline
- First posted
- 2017-03-01
- Last updated
- 2018-05-21
Source: ClinicalTrials.gov record NCT03067935. Inclusion in this directory is not an endorsement.